VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

A Novartis Pharmaceuticals Corporation Phase III study of Afinitor® (everolimus) tablets in combination with Sandostatin® LAR Depot (octreotide acetate for injectable suspension) extended median progression-free survival (PFS), or time without tumor growth, in patients with advanced carcinoid tumors compared to taking octreotide LAR alone.

11 Oct 2010

Role of TGF-ß in cancer diseases

During this year's BIOTECHNICA exhibition, the international biotech news magazine „GEN - Genetic Engineering & Biotechnology News yesterday on 5 October 2010, held an information event with subsequent panel discussion featuring the topic TGF-ß an important target in cancer diseases.

7 Oct 2010

AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) will be presented at the Ninth International Kidney Cancer Symposium (IKCS) in Chicago, Illinois, October 1-2, 2010.

4 Oct 2010

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that AVEO has regained worldwide rights from Merck (through its subsidiary, Schering Corporation) to develop and commercialize AV-299 (also known as SCH 900105), its anti-hepatocyte growth factor (HGF) antibody candidate.

30 Sep 2010

Circadian partners with Cincinnati Children's Hospital to develop blood test diagnostic for LAM, a serious lung disease

Circadian Technologies (ASX.CIR) has announced today that it has partnered with Cincinnati Children’s Hospital Medical Centre (CCHMC) to develop and market a blood test to diagnose LAM, a serious lung disease that strikes women, usually in their child bearing years.

29 Sep 2010

Unique genetic markers point to patient response to SCV-07 treatment

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that researchers have identified two unique gene clusters that differentiated subjects who responded to treatment in the Company’s phase 2a proof of concept study of SCV-07 for the prevention of severe oral mucositis (OM; WHO grades 3-4) in patients with advanced head and neck cancer.

29 Sep 2010

Researchers identify biomarker to predict tivozanib drug resistance

Researchers believe there may be a way to predict, based on individual tumors, those patients that are more likely to respond to the investigational new drug tivozanib.

29 Sep 2010

Pieris enters multi-year collaboration with Sanofi-Aventis and Sanofi Pasteur for Anticalin technology

Pieris AG announced today the signature of a collaboration and license agreement with both Sanofi-Aventis and Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, under which Pieris will apply its proprietary Anticalin technology to discover novel Anticalin drugs against multiple targets, with further development undertaken by Sanofi-Aventis and Sanofi-Pasteur. The collaboration will initially involve two targets nominated by Sanofi-Aventis and Sanofi-Pasteur, and includes the option for four additional targets.

29 Sep 2010

FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011.

23 Sep 2010

AACR to host fourth International Conference on Molecular Diagnostics

The American Association for Cancer Research will host its Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development from Sept. 27-30, 2010, at the Sheraton Denver Downtown in Denver, Colo.

22 Sep 2010

Pazopanib drug reduces thyroid cancer progression: Study

The drug pazopanib may help revolutionize the care of patients with metastatic, rapidly progressive differentiated thyroid cancers, say researchers at Mayo Clinic who are publishing findings of a phase II clinical trial in The Lancet Oncology.

18 Sep 2010

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Genentech, Inc., a member of the Roche Group, today announced that information submitted by the company to the U.S. Food and Drug Administration (FDA) during the review of the supplemental Biologics License Applications (sBLAs) for Avastin (bevacizumab) for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment.

18 Sep 2010

GSK, Genmab to refocus on ofatumumab development program in autoimmune indications

GlaxoSmithKline and Genmab A/S Following the 1st July announcement by GSK and Genmab of an amendment to the collaborative agreement for ofatumumab in which GSK assumed development responsibility for autoimmune indications, GSK and Genmab announced today plans to refocus the development program of ofatumumab in autoimmune indications.

16 Sep 2010

Genmab announces update in corporate strategy

Genmab A/S announced today an update to its corporate strategy. Today's strategy update represents a new beginning for Genmab where we acknowledge our successes and learn from our mistakes.

14 Sep 2010

Genmab, Seattle Genetics enter ADC research collaboration agreement

Genmab A/S and Seattle Genetics, Inc. announced today that the companies have entered into an antibody-drug conjugate (ADC) research collaboration agreement.

14 Sep 2010

Genmab announces Phase II ofatumumab study results in RRMS patients

Genmab A/S announced today encouraging results from an ofatumumab Phase II safety and pharmacokinetics study in patients with relapsing-remitting multiple sclerosis (RRMS).

13 Sep 2010

Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase 3 VELOUR clinical trial of aflibercept (VEGF Trap) in patients with metastatic colorectal cancer (mCRC) will continue to completion as planned, with no modifications due to efficacy or safety concerns. This decision is based on the recommendation of an Independent Data Monitoring Committee (IDMC) following a planned interim analysis.

9 Sep 2010

$GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL$

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

GlaxoSmithKline and Genmab A/S announced today the start of a Phase III study in patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL) who did not respond to or progressed during, or within 6 months of a rituximab containing regimen.

9 Sep 2010

Silence Therapeutics receives two patents for RNA interference therapeutics

Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).

8 Sep 2010

Nanoparticle-based gene silencing system inhibits angiogenesis process in tumor growth

A protein associated with cancer progression when abundant inside of tumors also unexpectedly regulates the creation of new blood vessels that feed the tumor outside, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the August edition of Cancer Cell.

17 Aug 2010

VEGF News and Research

Further Reading

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

Role of TGF-ß in cancer diseases

AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

Circadian partners with Cincinnati Children's Hospital to develop blood test diagnostic for LAM, a serious lung disease

Unique genetic markers point to patient response to SCV-07 treatment

Researchers identify biomarker to predict tivozanib drug resistance

Pieris enters multi-year collaboration with Sanofi-Aventis and Sanofi Pasteur for Anticalin technology

FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer

AACR to host fourth International Conference on Molecular Diagnostics

Pazopanib drug reduces thyroid cancer progression: Study

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

GSK, Genmab to refocus on ofatumumab development program in autoimmune indications

Genmab announces update in corporate strategy

Genmab, Seattle Genetics enter ADC research collaboration agreement

Genmab announces Phase II ofatumumab study results in RRMS patients

Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

Silence Therapeutics receives two patents for RNA interference therapeutics

Nanoparticle-based gene silencing system inhibits angiogenesis process in tumor growth

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Latest eBooks

Industry focus eBook - The Digital Laboratory (4th edition)

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (3rd Edition)

BFEB: Advances in microplate-based assays and analysis

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation